Figure 1

GQD significantly improved glycemic control and HOMA-β in T2D patients. (a) Change in FBG, (b) change in HbA1c and (c) change in HOMA-β. Placebo (n=41), LD (n=50), MD (n=52) and HD (n=44). Data are presented as mean±S.E.M. *P<0.05, **P<0.01 and ***P<0.001 vs placebo using ANCOVA; ⁺P<0.05, ⁺⁺P<0.01 and ⁺⁺⁺P<0.001 vs LD using ANCOVA.